Clinical trials in Treviso – page 15

920 clinical trials in Treviso, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Treviso at a glance

920

clinical trials

Research sites1

Quick filters

920 trials in Treviso

Open in trial search

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capivasertib
Sponsor:Relay Therapeutics Inc.

Contact Research Centre

Astrocytoma malignant

Recruiting

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Vorasidenib
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Renal cell carcinoma

Recruiting

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Belzutifan
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Hereditary angioedema

Recruiting

A Study of ADX-324 to Prevent Attacks in Patients With Hereditary Angioedema

Investigational

A Study of ADX-324 to Prevent Attacks in Patients With Hereditary Angioedema

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:ADX-324
Sponsor:Adarx Pharmaceuticals Inc.

Contact Research Centre

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:DB-1303
Sponsor:BioNTech SE

Contact Research Centre

Chronic graft versus host disease

Recruiting

Study of axatilimab compared to standard therapy in children with chronic graft-versus-host disease who have previously received at least 2 treatments

InvestigationalNo placebo

Study of axatilimab compared to standard therapy in children with chronic graft-versus-host disease who have previously received at least 2 treatments

InvestigationalNo placebo

Italy

Participants:0–17 years
Substances:Axatilimab
Sponsor:Incyte Corp.

Contact Research Centre

Rectal cancer

Recruiting

Study of XELOX chemotherapy with or without dostarlimab after chemoradiation in patients with locally advanced rectal cancer

Registered drugNo placebo

Study of XELOX chemotherapy with or without dostarlimab after chemoradiation in patients with locally advanced rectal cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica

Contact Research Centre

Nasopharyngeal cancer

Recruiting

Study of toripalimab, cisplatin and gemcitabine combination as first treatment for patients with recurrent or metastatic nasopharyngeal cancer

Registered drugNo placebo

Study of toripalimab, cisplatin and gemcitabine combination as first treatment for patients with recurrent or metastatic nasopharyngeal cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:Humanitas Mirasole S.p.A.

Contact Research Centre

Generalised tonic-clonic seizure+1

Recruiting

Study of PRAX-628 to evaluate safety and effectiveness in adults with epilepsy who have focal seizures or generalized tonic-clonic seizures

InvestigationalNo placebo

Study of PRAX-628 to evaluate safety and effectiveness in adults with epilepsy who have focal seizures or generalized tonic-clonic seizures

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Vormatrigine
Sponsor:Praxis Precision Medicines Inc.

Contact Research Centre

Acute myeloid leukaemia+3

Recruiting

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Busulfan
Sponsor:Medizinische Hochschule Hannover

Contact Research Centre

Vulval cancer

Recruiting

Study of pembrolizumab and lenvatinib treatment for patients with vulvar cancer

Registered drugNo placebo

Study of pembrolizumab and lenvatinib treatment for patients with vulvar cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Lenvatinib
Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Treviso

What the registry says about research in the country

01 Hematologic Oncology

Innovative trials exploring treatments for Acute Myeloid Leukemia and Lymphomas, including studies on targeted therapies combined with standard chemotherapy. Research focuses on improving treatment outcomes for various blood cancers.

Gemtuzumab Ozogamicin for AML
Daratumumab for Plasmablastic Lymphoma
Follicular Lymphoma Treatment Optimization

Advanced therapeutic approaches aim to enhance minimal residual disease control and patient outcomes.

02 Gynecologic Oncology

Comprehensive research into ovarian cancer treatments, including studies of maintenance therapies and novel drug combinations. Investigations focus on both recurrent and newly diagnosed cases.

Olaparib Maintenance Therapy
Low-grade Serous Carcinoma Treatment
Cervical Cancer Prevention

Studies emphasize personalized treatment approaches based on specific genetic markers and disease characteristics.

03 Respiratory Medicine

Groundbreaking research in lung cancer and severe respiratory conditions, including targeted therapies for specific genetic mutations and innovative treatment combinations.

ALK-positive NSCLC Treatment
Small Cell Lung Cancer Therapy
Severe Asthma Management

Focus on developing personalized treatment strategies for various lung cancer subtypes and respiratory conditions.

Back to Italy All countries